Denali therapeutics reports first quarter 2021 financial results and business highlights

South san francisco, calif., may 03, 2021 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (bbb) for neurodegenerative diseases, today reported financial results for the first quarter ended march 31, 2021, and provided business highlights.
DNLI Ratings Summary
DNLI Quant Ranking